Novo Nordisk's 1st TBL Quarterly
of 2014

Novo Nordisk has become the first pharmaceutical company in the world to publish an Environmental Profit and Loss (E P&L) account. The story behind the E P&L is told in the latest issue of Novo Nordisk’s sustainability magazine – TBL Quarterly.

Download the issue here.

The results of the E P&L show the total environmental costs related to water consumption, greenhouse gas (GHG) emissions, and air pollution, analysing how the company can manage risks and identify areas with potential for reductions.

“Novo Nordisk has a long history of environmental responsibility and we continuously seek to provide transparent disclosures of practices and performance. The E P&L is a natural next step in this journey,” says Susanne Stormer, vice president, Corporate Sustainability, Novo Nordisk.

In addition to Novo Nordisk’s E P&L, the new issue of TBL Quarterly looks behind the annual social and environmental performance numbers to tell the stories of how the company works with business ethics, company diversity and environmental, social and governance (ESG) data management.

The TBL Quarterly is published four times a year. If you want to receive notification when new issues are available, send a mail to sustainability@novonordisk.com.

About the TBL Quarterly
Novo Nordisk manages its business in accordance with the Triple Bottom Line (TBL) business principle and pursues business solutions that maximise value to both stakeholders and shareholders. Through selected themes, new perspectives and personal stories, the TBL Quarterly demonstrates how our Triple Bottom Line business principle supports long-term value creation. The TBL Quarterly is available as a reader-friendly PDF.

Explore previous issues of the TBL Quarterly.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk